Cell Reprogramming Market Size & Share, by Stem Cells Type (Adult, Human Embryonic, Induced Pluripotent, Small Embryonic); End-User (Hospitals, Research Organizations, Toxicity Test); Derived Cell Types (Fibroblasts, Amniotic, Hepatocytes, Keratinocytes); Application (Drug Development, Regenerative Medicine); Reprogramming Type (Episormal, RNA, Retrovirus, Lentivirus, Sendai Virus-based) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5835
  • Published Date: Mar 08, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Cell Reprogramming Market size is expected to reach USD 1 Billion by the end of 2036, growing at a CAGR of 6% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of cell reprogramming was USD 400 Million. The reason behind the growth is impelled by the growing burden of cancer across the globe. Developing nations will bear a disproportionate share of the cost of cancer incidence, morbidity, and mortality owing to rising levels of air pollution, unhealthy diets, drinking alcohol, smoking, and not moving around much.

According to the World Health Organization (WHO), it is anticipated that there will be over 35 million new cases of cancer in 2050, a 77% increase over the projected 20 million cases in 2022. 

The growing advancements in technology are believed to fuel the market growth. For instance, researchers have reported using a cellular reprogramming technique to create neural networks that mimic distinct features of human cells which could facilitate the development of new treatments for neuropathies.


Cellular Reprogramming Tools Market
Get more information on this report: Request Free Sample PDF

Cell Reprogramming Sector: Growth Drivers and Challenges

Growth Drivers

  • Rising Adoption of Regenerative Medicine- The term "cellular reprogramming" describes the act of changing a cell's fate, or changing its kind, which is known to hold a great promise for the field of regenerative medicine.
  • Growing Popularity of Personalized Medicine- By first evaluating the safety of already approved medications on reprogrammed patient cells in a customized way before they are administered, reprogramming may help precision medicine, which seeks to deliver individualized medical treatment.
  • Surging Prevalence of Neurodegenerative Diseases- Age-related neurodegenerative disorders and other late-onset diseases have been well modeled in cell culture to assist researchers in their studies of the aging process in addition to helping them create new therapeutic approaches.

As per the World Health Organization (WHO), currently, about 55 million individuals globally suffer from dementia, with more than 60% residing in low- and middle-income nations.

  • Increasing Geriatric Population- Reprogramming possesses the amazing capacity to undo some cellular and molecular traits linked to aging, and can also improve the comprehension of human aging mechanisms and aid in the discovery of anti-aging medications. For instance, more than 770 million individuals worldwide were 65 years of age or older in 2022, making up about 9% of the world's population.

Challenges

  • Stringent Regulatory Requirements- Adhering to strict and durable conditions for cell culture is necessary for iPS cells and cell reprogramming to produce iPSCs of superior quality for use in medicinal settings.
  • Technical complexity may increase the need for specialized expertise and limit the accessibility to researchers with a lack of resources
  • The high cost of Cell Reprogramming may limit their adoption

Cell Reprogramming Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

~6%

Base Year Market Size (2023)

~ USD 400 Million

Forecast Year Market Size (2036)

~ USD 1 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Cell Reprogramming Segmentation

Product Type (Adult Stem Cells, Human Embryonic Stem Cells, Induced Pluripotent Stem Cells, Small Embryonic Like Stem Cells)

The induced pluripotent stem cells segment is predicted to account for 45% share of the global cell reprogramming market by 2036. owing to the growing usage by scientists and researchers. Induced pluripotent stem cells are used by modern scientists and researchers to investigate human development, and have been applied to numerous scientific investigations and clinical trials, such as those involving disease modeling, regenerative medicine, and drug cytotoxicity and discovery studies. The development of iPSCs has revolutionized stem cell research and created exciting new opportunities for improving cancer treatment, understanding tumor progression, cell treatment, immunotherapy, and cancer modeling. Researchers have also been looking at the possibility of treating several disorders with iPS cells, and have been striving to advance the methods and discover the mechanisms behind pluripotent stem cell differentiation.

Moreover, there is a lot of optimism for the therapeutic use of induced pluripotent stem cells (iPSCs) in several disorders as researchers may now address disease characteristics and how they progress in a cell culture plate by using pathogenic cells produced from patient cells.

 End-User (Hospitals, Research Organizations, Toxicity Test)

The research organizations segment in cell reprogramming market is set to garner a notable share shortly. For scientists doing stem cell research, superior cellular reprogramming techniques were created, which is a fascinating field of biomedical engineering study that involves the direct conversion of an adult cell from one type to another. For instance, more information regarding naïve stem cell reprogramming has been made available to researchers from the Babraham Institute's Epigenetics research group that outlines the crucial regulators of reprogramming for a more effective method of producing human naïve pluripotent stem cells.

Our in-depth analysis of the global market includes the following segments:

     Product Type

  • Adult Stem Cells
  •  Human Embryonic Stem Cells
  •  Induced Pluripotent Stem Cells
  •  Small Embryonic Like Stem Cells

     End-User

  • Hospitals
  •  Research Organizations
  •  Toxicity Test

     Derived Cell Types

  • Fibroblasts
  •  Amniotic cells
  •  Hepatocytes
  •  Keratinocytes

     Application

  • Drug Development
  •  Regenerative Medicine

     Reprogramming Type

  • Episormal, RNA
  •  Retrovirus
  •  Lentivirus
  •  Sendai Virus-based

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Cell Reprogramming Industry - Regional Synopsis

North American Market Forecast

Cell reprogramming market in North America is predicted to account for the largest share of 44% by 2036 impelled by the growing adoption of cloud-based solutions. Cloud computing is becoming more and more popular in the United States since it greatly improves communication between patients, providers, and stakeholders in the healthcare industry. For instance, by 2026, more than 65% of all hospitals and health systems in the US will probably have implemented a cloud-based supply chain management strategy, which will aid in improving decision-making, increasing agility and efficiency, and streamlining procedures. This may drive the demand for Cell Reprogramming as researchers extensively rely on cloud platforms to support their studies.

APAC Market Statistics

The Asia Pacific cell reprogramming market is estimated to be the second largest, during the forecast timeframe led by the growing advancements in biomedical research. The substantial investments made by the Indian government in biomedical engineering research and development are opening up more opportunities for biomedical research which are currently being redefined by groundbreaking developments in gene- and cell-based treatment. In addition, the Indian government has expressed interest in advancing stem cell and regenerative medicine though the area of regenerative medicine is still in its infancy, there have been encouraging advancements, and interest in innovation and entrepreneurship.

Research Nester
Cellular Reprogramming Tools Market SIZE
Get more information on this report: Request Free Sample PDF

Companies Dominating the Cell Reprogramming Landscape

top-features-companies
    • Celgene Corporation
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Human Longevity Inc.
    • BIOTIME, INC.
    • Mesoblast
    • Advanced Cell Technology Inc
    • Osiris Therapeutics Inc.
    • STEMCELL Technologies Inc.
    • Astellas Pharma Inc.

In-the-news

In The News

  • Altos Labs with the help of cellular rejuvenation programming announced to reverse aging and disease processes which also has the promise of revolutionizing our understanding of human illness.
  • Mesoblast announced a partnership with Blood and Marrow Transplant Clinical Trials Network (BMT CTN) for a clinical investigation and carry out the study that will assess Ryoncil in individuals 12 years of age and older who have not responded to first-line therapies such as corticosteroids or ruxolitinib.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5835
  • Published Date: Mar 08, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

the growing burden of cancer across the globe and the growing advancements in technology are the major factors driving the growth of the market.

The market size of Cell Reprogramming is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2024-2036.

The major players in the market are Osiris Therapeutics Inc., Astellas Pharma Inc., FUJIFILM Holdings Corporation, EVOTEC, Japan Tissue Engineering Co., Ltd, Celgene Corporation, BIOTIME, INC., Human Longevity Inc., Advanced Cell Technology Inc, STEMCELL Technologies Inc., and others.

The Induced Pluripotent Stem Cells segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Cell Reprogramming Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying